axonics modulation technologies, inc is a privately-held medical device company developing an innovative neuromodulation platform based on a miniaturized rechargeable fully-implantable ipg licensed from the alfred mann foundation. the axonics sacral neuromodulation system is designed to improve the experience of both clinicians and patients suffering from urinary and fecal dysfunction.
Company profile
Ticker
AXNX
Exchange
Website
CEO
Raymond Cohen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Axonics Modulation Technologies, Inc.
SEC CIK
Corporate docs
Subsidiaries
Axonics Europe, S.A.S. • Axonics Modulation Technologies, U.K. Limited • Axonics Modulation Technologies Australia Pty Ltd • Axonics Women’s Health Limited • Bulkamid SARL • Axonics GmbH • Contura, Inc. ...
IRS number
454744083
AXNX stock data
Latest filings (excl ownership)
8-K
Axonics Stockholders Approve Merger Agreement with Boston Scientific
25 Mar 24
DEFA14A
Additional proxy soliciting materials
7 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results
28 Feb 24
DEFM14A
Proxy related to merger
22 Feb 24
PREM14A
Preliminary proxy related to merger
6 Feb 24
DEF 14A
Definitive proxy
8 Jan 24
8-K
Entry into a Material Definitive Agreement
8 Jan 24
8-K
Axonics Reports Preliminary 4Q23 and Fiscal Year 2023 Revenue
8 Jan 24
10-Q
2023 Q3
Quarterly report
30 Oct 23
Transcripts
AXNX
Earnings call transcript
2023 Q3
30 Oct 23
AXNX
Earnings call transcript
2023 Q2
28 Jul 23
AXNX
Earnings call transcript
2023 Q1
1 May 23
AXNX
Earnings call transcript
2022 Q4
1 Mar 23
AXNX
Earnings call transcript
2022 Q3
31 Oct 22
AXNX
Earnings call transcript
2022 Q2
2 Aug 22
AXNX
Earnings call transcript
2022 Q1
8 May 22
AXNX
Earnings call transcript
2021 Q4
25 Feb 22
AXNX
Earnings call transcript
2021 Q3
7 Nov 21
AXNX
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 147.32 mm | 147.32 mm | 147.32 mm | 147.32 mm | 147.32 mm | 147.32 mm |
Cash burn (monthly) | (no burn) | 7.83 mm | (no burn) | 2.21 mm | (no burn) | (no burn) |
Cash used (since last report) | n/a | 46.83 mm | n/a | 13.22 mm | n/a | n/a |
Cash remaining | n/a | 100.49 mm | n/a | 134.10 mm | n/a | n/a |
Runway (months of cash) | n/a | 12.8 | n/a | 60.6 | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 223 |
Opened positions | 40 |
Closed positions | 53 |
Increased positions | 80 |
Reduced positions | 76 |
13F shares | Current |
---|---|
Total value | 2.77 tn |
Total shares | 56.46 mm |
Total puts | 56.30 k |
Total calls | 67.60 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 5.26 mm | $295.32 bn |
FMR | 4.56 mm | $255.82 bn |
BLK Blackrock | 3.91 mm | $219.66 bn |
BLVGF Bellevue | 2.25 mm | $126.43 bn |
Champlain Investment Partners | 2.01 mm | $112.99 bn |
Andera Partners | 1.99 mm | $107.37 mm |
Longitude Capital Partners III | 1.96 mm | $100.70 mm |
Bamco | 1.80 mm | $101.00 bn |
AXAHF Axa | 1.73 mm | $96.98 bn |
IVZ Invesco | 1.63 mm | $91.76 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
31 Jan 24 | Sama Rinda | Common Stock | Option exercise | Acquire M | No | No | 0 | 28,000 | 0.00 | 83,854 |
31 Jan 24 | Sama Rinda | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 17,500 | 0.00 | 0 |
31 Jan 24 | Sama Rinda | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 10,500 | 0.00 | 0 |
31 Jan 24 | Karen Noblett | Common Stock | Sell | Dispose S | No | No | 67.7359 | 11,288 | 764.60 k | 34,428 |
31 Jan 24 | Karen Noblett | Common Stock | Option exercise | Acquire M | No | No | 0 | 27,500 | 0.00 | 45,716 |
31 Jan 24 | Karen Noblett | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 15,000 | 0.00 | 0 |
31 Jan 24 | Karen Noblett | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 6,500 | 0.00 | 0 |
31 Jan 24 | John Woock | Common Stock | Sell | Dispose S | No | No | 67.7359 | 15,899 | 1.08 mm | 77,403 |
31 Jan 24 | John Woock | Common Stock | Option exercise | Acquire M | No | No | 0 | 28,000 | 0.00 | 93,302 |
31 Jan 24 | John Woock | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 17,500 | 0.00 | 0 |
News
Axonics Stockholders Approve Merger Agreement With Boston Scientific; Expected To Occur In The First Half Of 2024 And Remains Subject To Certain Conditions
22 Mar 24
Axonics Updates On Inter Partes Review Proceedings; Plans To Seek Review Of The PTAB's Finding That Remaining Claims Were Not Unpatentable
21 Mar 24
Axonics Responds To ITC Action By Medtronic; CEO Says "We Believe Medtronic's Claims Are Designed To Stifle Competition, Limit Patient And Physician Choice, And Protect The Incumbent's Market Position"
29 Feb 24
Beyond The Numbers: 7 Analysts Discuss Axonics Stock
29 Feb 24
RBC Capital Reiterates Sector Perform on Axonics, Maintains $71 Price Target
29 Feb 24
Press releases
Axonics Stockholders Approve Merger Agreement with Boston Scientific
22 Mar 24
Axonics Provides Update on Inter Partes Review Proceedings
21 Mar 24
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
14 Mar 24
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates MDC, AXNX, CPE
2 Mar 24
Axonics Responds to ITC Action by Medtronic
29 Feb 24